CHIP BCIS3

Issue no.15 May 2024

BREAKING NEWS

PATIENTS RECRUITED

221

300

Three Hundred

Divaka Perera
CI of CHIP-BCIS3

I am delighted to share some good news about the trial - thanks to your untiring efforts, and against the odds, we have managed to stay on track with the recruitment rate that was projected at the start of the trial. This is unusual for RCTs of this sort and both the TSC and HTA programme committee were really pleased to see this. As a result, they have just **approved our application to extend the trial sample size to 300!** This will increase the likelihood of us delivering a definitive result that will therefore have the potential to change treatment guidelines.

Importantly, we plan to do this without changing the overall trial duration, which means that we need to recruit the remaining **79 patients in the next 6 months.** Based on recent recruitment, this certainly seems feasible; we will contact each of you in the next few weeks to discuss individual targets and strategies.

CHIP-BCIS3 Leaderboard



DanGer

Results of the eagerly anticipated DanGer-Shock trial were presented and published in April this year. A RCT of percutaneous LVAD (Impella) therapy versus standard of care in patients with cardiogenic shock, I think this trial was remarkable for many reasons: firstly, it is one of the first therapies shown to be effective at improving survival from cardiogenic shock in more than 30 years. It is also the first robust randomised evidence for efficacy of Impella in any clinical setting. Finally, it is a real testament to the value of evaluating therapeutic strategies in randomised trials – the investigators persisted for 10 years to recruit 360 patients and in doing so have provided much needed data that will guide management of these patients in the future.



Møller JE *et al.* NEJM 2024;390

Q Do these results affect CHIP-BCIS3?

A

In short, no.

DanGer recruited a very different cohort of patients and the results cannot be extrapolated to high risk PCI, where patients are NOT in cardiogenic shock at the start of the procedure.

The 4th of July

CHIP-BCIS3 INVESTIGATORS' MEETING

Our **next investigator meeting** will be on the 4th of July 2024, from 3:30 to 5pm. This will be online and we will email a link to those who register to attend (there will also be an option for anyone who happens to be in London that day to join the rest of the team at St Thomas' for the meeting– venue TBC).

DATE
4th July 2024

Our keynote speaker will be none other than Jacob Møller, the Chief Investigator of DanGer Shock!

TIME
3:30 - 5pm

I hope most of you will join us for a unique opportunity to discuss DanGer with Dr Møller himself and to hear an update on CHIP-BCIS3 as well as details of the strategy for our final recruitment push. If you would like to attend, please contact the CTU directly using the email address below.

Jacob Møller

Yes, it is UK Election Day ... don't worry, there will still be plenty of time to cast your ballot after the meeting finishes!

CONTACT US

If you have any questions please don't hesitate to contact the CTU team - Matt Kwok, Megan Knight, Laura Van Dyck and Richard Evans.

Email: CHIP-BCIS3@LSHTM.ac.uk
Tel: +44 (0)20 7927 2723
Twitter: @CHIP_BCIS3

NHS Guy's and St Thomas' NHS Foundation Trust · King's College London · London School of Hygiene & Tropical Medicine